Viome
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 15.9m | 25.2m | 26.0m | 29.0m | 29.0m | 29.0m |
% growth | - | 58 % | 3 % | 12 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $15.0m | Series A | |
$5.5m | Series B | ||
$25.0m | Series B | ||
N/A | $3.0m | Debt | |
* | $54.0m | Convertible | |
* | $67.0m | Series C | |
* | $19.5m | Series C | |
* | $25.0m Valuation: $335m | Series D | |
Total Funding | €192m |
Related Content
Recent News about Viome
EditViome operates in the health and wellness market, focusing on personalized nutrition and gut health solutions. The company serves individuals seeking to optimize their health through tailored dietary and supplement recommendations. Viome's core business model revolves around offering health tests that analyze the microbiome and cellular health, providing personalized insights and nutrition plans based on the results. The company leverages advanced mRNA technology and artificial intelligence to deliver precise health recommendations. Revenue is generated through the sale of health tests, personalized supplements, and probiotics subscriptions. Viome's target market includes health-conscious consumers looking for data-driven, personalized health solutions.
Keywords: microbiome, personalized nutrition, gut health, mRNA technology, AI platform, health tests, probiotics, supplements, cellular health, wellness.